Welcome to the Pacific Edge Investor Centre. Here you will find useful information about being a shareholder of our company.
See the latest news and presentations, keep up to date with our newsletters and shareholder reports, find out when we are holding shareholder meetings and check up on our share price.
Pacific Edge is a publicy listed company on the NZX: listed as PEB.
- Value $00,000.000
- Volume 00,000
- Capitalisation $000,000
- Open $0.000
- Close $0.000
- High $0.000
- Low $0.000
Data up to date as of 00-00-0000 00:00
Pacific Edge receives approval for new CPT codes from AMA
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), advises that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted Administrative MAAA CPT codes for Pacific Edge's Cxbladder Detect and Cxbladder Monitor tests. [read more]
Pacific Edge ranked number 5 in inaugural Financial Times FT 1000 High Growth Companies Asia-Pacific
Pacific Edge Limited is delighted to have been ranked number 5 in the inaugural Financial Times FT 1000 High Growth Companies Asia-Pacific [read more]
Pacific Edge Signs Contract with MediNcrease Health Plan in US
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has entered into an agreement with MediNcrease Health Plans, LLC, a national provider network in the United States, to make Cxbladder available to 5.5 million covered lives through its clients and payers. [read more]
Reports and Presentations
For further investor information on Pacific Edge our recent annual reports, investor presentations and investment research reports are available for download below
FY17 Full Year Results Conference Call Audio Commentary[5.8 MB]
FY17 Full Year Results Presentation[3.1 MB]